Center for Cancer Immunology and Immunotherapy (CCII)

癌症免疫学和免疫治疗中心 (CCII)

• 批准号: 10093098
• 负责人: Jason A. Chesney
• 金额: $ 232.47万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10093098
• 关键词: Adoptive Cell Transfers; Advanced Malignant Neoplasm; Advisory Committees; Animals; Antibodies; Area; Award; Basic Science; Bioinformatics; Biological Markers; Biomedical Research; Biometry; Bladder; CAR T cell therapy; CTLA4 gene; Cancer Center; Cancer Death Rates; Centers of Research Excellence; Clinical; Clinical Trials; Collaborations; Conduct Clinical Trials; Country; Cytometry; Development; Diagnosis; Discipline; Disease remission; Disseminated Malignant Neoplasm; Early Diagnosis; Financial Support; Flow Cytometry; Funding; Future; Genomics; Goals; Grant; Growth; Head and neck structure; Home; Human; Human Resources; Immune; Immune Evasion; Immune checkpoint inhibitor; Immune response; Immune system; Immunity; Immunologic Surveillance; Immunologist; Immunotherapeutic agent; Immunotherapy; Infrastructure; Institution; Interdisciplinary Study; International; Kidney; Lead; Lung; Malignant Neoplasms; Mediating; Mentors; Mission; Molecular; Mus; Names; Oncolytic viruses; Outcome; Paper; Patients; Persons; Phase; Pilot Projects; Proteins; Publications; Recording of previous events; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Resistance; Resources; Sampling; Savings; Seminal; Services; Specimen; Study Section; T cell therapy; Talents; Testing; Training; Translating; Translational Research; Universities; Vaccines; Work; anti-cancer; base; cancer cell; cancer clinical trial; cancer immunotherapy; cancer therapy; cancer type; career development; checkpoint therapy; cohort; equipment acquisition; immune checkpoint; improved; innovation; interest; melanoma; member; microbiome research; new therapeutic target; novel strategies; optimism; programmed cell death ligand 1; programmed cell death protein 1; programs; recruit; research and development; response; senior faculty; side effect; success; systemic toxicity; treatment strategy; tumor; tumor immunology

The objective of this program is to establish a thematic multidisciplinary research center of excellence at the University of Louisville (UofL) named the Center for Cancer Immunology and Immunotherapy (CCII). The mission of the CCII is to conduct outstanding biomedical research that works towards harnessing the power of the immune system to eradicate cancer. There is currently a great deal of optimism about the prospects for cancer immunotherapies given the recent clinical successes of immune checkpoint inhibitors, oncolytic viruses, and adoptive cell transfer therapies. Immunotherapies have the potential to be used to treat all types of cancer and to induce long-lasting remissions or cures. However, more research and development is needed for cancer immunotherapy to reach its full potential. The University of Louisville is exceptionally qualified to be the home of the CCII for many reasons including our 10-year track record of conducting clinical trials of immunotherapeutic agents, unique resources that include access to human specimens from these trials, our senior investigators’ expertise in cancer immunology, our focus on translational research, and the impact that this COBRE would have in a state with the highest cancer death rates in the nation. Importantly, the University of Louisville is highly invested in making this proposed center a success as best evidenced by more than $16.8M in institutional commitments over five years. The two PIs of the CCII program are highly regarded experts in the field who have made seminal contributions spanning from basic cancer immunology to pivotal clinical trials of cancer immunotherapies. Senior mentors with expertise in the thematic area and a strong history of funding, publications, mentoring, and study section service will support the CCII’s mentoring mission, as will a team of co-investigators with essential expertise (in administration, biostatistics, and bioinformatics) and Internal and External Advisory Committees. A Functional Immunomics Core will provide important new infrastructure and leverage existing resources (including other IDeA programs) to provide outstanding support to the four promising junior investigators who have been selected as the first cohort of CCII Project PIs. The four overall specific aims of the CCII are to: (1) Establish the administrative and mentoring infrastructure for the CCII; (2) Create a research core that provides new capabilities while leveraging existing facilities; (3) Support the research and career development of junior PIs in the thematic area; and (4) Develop and initiate a plan for long-term sustainability and growth of the CCII. We are confident that this new COBRE center will lead to the awarding of innovative R01 grants for 4-6 CCII junior investigators in the first five years and that many of these graduates will remain key members of this new COBRE to further build the center in the future. Most importantly, our combination of rigorous basic science with highly translational animal and human specimen studies should ultimately contribute to the development of new treatment strategies that will help to improve the outlook for the more than 17 million people worldwide who are diagnosed with cancer each year.

该计划的目标是建立一个卓越的主题多学科研究中心， 路易斯维尔大学（UofL）命名为癌症免疫学和免疫治疗中心（CCII）。的 CCII的使命是进行杰出的生物医学研究，致力于利用 免疫系统来根除癌症目前，人们对以下方面的前景非常乐观： 鉴于免疫检查点抑制剂，溶瘤病毒， 和过继细胞转移疗法。免疫疗法有可能用于治疗所有类型的癌症 并诱导持久的缓解或治愈。然而，需要更多的研究和开发， 癌症免疫疗法发挥其全部潜力。路易斯维尔大学非常有资格成为 CCII的发源地有很多原因，包括我们进行临床试验的10年跟踪记录， 免疫抑制剂，独特的资源，包括从这些试验中获得人类标本，我们的 高级研究人员在癌症免疫学方面的专业知识，我们对转化研究的关注，以及 这个眼镜蛇会出现在全国癌症死亡率最高的州。重要的是，大学 路易斯维尔市政府高度投入，使这个拟议中的中心取得成功，最好的证明是， 五年内机构承诺1 680万美元。CCII计划的两个PI受到高度重视 该领域的专家，他们做出了开创性的贡献，从基础癌症免疫学到关键的 癌症免疫疗法的临床试验具有专题领域专门知识和 资金、出版物、指导和研究部门服务的历史将支持CCII的指导使命， 一个具有基本专业知识（管理、生物统计和生物信息学）的共同研究者团队也将如此 以及内部和外部咨询委员会。功能性免疫组学核心将提供重要的新 基础架构并利用现有资源（包括其他IDEA计划）提供出色的支持 四位有前途的初级研究员获选为首批CCII计划的主要研究员。的 CCII的四个总体具体目标是：（1）建立管理和指导基础设施， CCII;（2）建立一个研究核心，在利用现有设施的同时提供新的能力;（3）支持 （4）制订及推行计划， CCII的长期可持续性和增长。我们相信，这个新的COBRE中心将导致 在前五年为4-6名CCII初级研究人员颁发创新R 01赠款，其中许多 毕业生将继续成为这个新的COBRE的关键成员，以进一步建设未来的中心。最 重要是，我们将严谨的基础科学与高度转化的动物和人类标本相结合， 研究最终应有助于开发新的治疗策略，这将有助于改善 全球每年有超过1700万人被诊断患有癌症。